Neurofibromatosis 1: recommendations for management, Ann Dermatol Vénéréol, vol.128, pp.567-575, 2001. ,
Malignant peripheral nerve sheath tumours in neurofibromatosis 1, J Med Genet, vol.39, pp.311-314, 2002. ,
Mortality in neurofibromatosis 1: an analysis using U.S. death certificates, Am J Hum Genet, vol.68, pp.1110-1118, 2010. ,
Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis, Eur J Surg Oncol, vol.21, pp.78-82, 1995. ,
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis, Cancer Res, vol.62, pp.1573-1577, 2002. ,
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis, Cancer Treat Rev, vol.30, pp.83-101, 2004. ,
Variance of SUVs for FDG-PET/CT is greater in clinical practice than Under idéal study settings, Clin Nucl méd, vol.38, pp.175-182, 2013. ,
Repeatability of 18 F-FDG uptake measurements in tumors :a metaanalysis, J Nucl Med, vol.53, pp.701-708, 2012. ,
Does (18)-FDG PET/CT add diagnostic accuracy in incidentally identified non secreting adrenal tumors?, Eur J Nucl Med Mol Imaging, vol.35, pp.2018-2025, 2008. ,
Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesion, Ann Nucl Med, vol.23, pp.349-354, 2009. ,
, National Institutes of Health Consensus Development Conference, Neurofibromatosis. Conference statement, vol.45, pp.575-578, 1998.
Intérêt de la scintigraphie au FDG 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1, Ann Dermatol Vénéréol, vol.134, pp.735-742, 2007. ,
Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1, Br J Dermatol, vol.153, pp.79-82, 2005. ,
Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET), Anticancer Res, vol.19, pp.4443-4450, 1999. ,
Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases, Am J Clin Pathol, vol.87, pp.425-433, 1987. ,
Malignant peripheral Nerve Sheath tumors (MPNST): The Mayo clinic experience, Ann Surg Oncol, vol.19, pp.878-885, 2012. ,
Malignant peripheral nerve sheath tumors in neurofibromatosis 1, Am J Med Genet, vol.93, pp.388-392, 2000. ,
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases, Cancer, vol.57, pp.2006-2021, 1986. ,
Association between benign and malignant peripheral nerve sheath tumors in NF1, Neurology, vol.65, pp.205-211, 1999. ,
Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis, Eur J Surg Oncol, vol.25, pp.190-193, 1999. ,
Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis, Am J Med Genet, vol.89, pp.23-30, 1999. ,
Malignant peripheral nerve sheath tumors of the head and neck: analysis of prognostic factors, Otolaryngol Head Neck Surg, vol.122, pp.667-672, 2000. ,
Survival in Malignant Peripheral Nerve Sheath Tumours: a comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours, Sarcoma, p.756395, 2009. ,
Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma, Cancer Radiother, vol.10, pp.185-207, 2006. ,
Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease, AJR Am J Roentgenol, vol.150, pp.615-620, 1988. ,
Magnetic resonance imaging of soft tissue tumors, J Belge Radiol, vol.75, pp.286-296, 1992. ,
The value of magnetic resonance imaging in the differentiation between malignant peripheral nerve-sheath tumors and nonneurogenic malignant soft-tissue tumors, Skeletal Radiol, vol.35, pp.745-753, 2006. ,
The target sign: extremity, Radiology, vol.234, pp.899-900, 2005. ,
Diagnosis of softtissue masses with MR imaging: can benign masses be differentiated from malignant ones, Radiology, vol.185, pp.581-586, 1992. ,
Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy, Chest, vol.109, pp.982-988, 1996. ,
Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities, J Nucl Med, vol.35, pp.1771-1776, 1994. ,
18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis, Nuklearmedizin, vol.43, pp.91-104, 2004. ,
Dynamic changes of FDG Uptake and clearance in normal tissues, Mol Imaging Biol, vol.15, pp.345-352, 2013. ,
Detection of liver metastases from pancreatic cancer using FDG PET, J Nucl Med, vol.40, pp.250-255, 1999. ,
Differentiating benign from malignant lung lesions using ''quantitative'' parameters of FDG PET images, Clin Nucl Med, vol.21, pp.941-949, 1996. ,
18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1, Eur J Nucl Med Mol Imaging, vol.36, pp.751-757, 2009. ,
Usefulness and limitations of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for detection of malignancy of orbital tumors, Neurol Med Chir (Tokyo), vol.48, pp.495-499, 2008. ,
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign, Cancer, vol.116, pp.451-458, 2010. ,
FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report, Ann Nucl Med, vol.19, pp.55-58, 2005. ,
18-FDG-PET in a case of recurrent malignant schwannoma, Rev Esp Med Nucl, vol.24, pp.127-130, 2005. ,
Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET, Clin Nucl Med, vol.29, pp.415-418, 2004. ,
Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis, Clin Nucl Med, vol.26, pp.525-528, 2001. ,
Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours, Eur J Surg Oncol, vol.29, pp.536-541, 2003. ,
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours, Eur J Nucl Med Mol Imaging, vol.33, pp.428-432, 2006. ,
Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with mailgnant transformation, J Neurooncol, vol.108, issue.18, pp.469-475, 2012. ,
Potential role of (18)-Fluorodeoxyglucose positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1, Neurosurgery, vol.65, pp.160-170, 2009. ,
Evaluation of (18) fluorodeoxyglucose positron emission tomography ((18) FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1, J Neurol Neurosurg Psychiatry, vol.68, pp.353-357, 2000. ,
18F) 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study, Ann Oncol, vol.19, pp.390-394, 2008. ,
Is liver stable over time in 18 F-FDG PET imaging, J Nucl Med Technol, vol.39, pp.258-263, 2011. ,
Falsenegative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of a neurofibromatosis type 1, J Surg Orthop Adv, vol.20, pp.132-135, 2011. ,
18-Fluorodeoxyglucose positron emission tomography FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST), Pediatr Blood Cancer, vol.60, pp.59-64, 2013. ,